Tech Center 1600 • Art Units: 1600 1612 1624
This examiner grants 63% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18582123 | Membrane Encapsulated Nanoparticles and Method of Use | Non-Final OA | The Regents of the University of California |
| 18320928 | NANOSCALE COATINGS FOR ENCAPSULATION OF BIOLOGICAL ENTITIES | Non-Final OA | The Regents of the University of California |
| 18332324 | HIGH-THROUGHPUT METHODS FOR PREPARING LIPID NANOPARTICLES AND USES THEREOF | Final Rejection | GENENTECH, INC. |
| 18549645 | DRY POWDER FORMULATIONS OF NUCLEIC ACID LIPID NANOPARTICLES | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17758059 | COSMETIC COMPOSITION COMPRISING A CATIONIC ASSOCIATIVE POLYMER, A CARBOXYLIC ANIONIC SURFACTANT, OPTIONALLY A NONIONIC SURFACTANT AND AN AMPHOTERIC OR ZWITTERIONIC SURFACTANT | Non-Final OA | L'Oreal |
| 18159675 | LIPOSOMES ENCAPSULATING ADENOSINE | Final Rejection | New York University |
| 18952404 | PROTEIN-LOADED PLGA NANOSPHERES | Non-Final OA | West Virginia University Board of Governors on behalf of West Virginia University |
| 18946447 | PROTEIN-LOADED PLGA NANOSPHERES | Non-Final OA | West Virginia University Board of Governors on behalf of West Virginia University |
| 18939439 | AGENTS, COMPOSITIONS AND METHODS FOR ENHANCED DELIVERY OF NUCLEIC ACIDS TO THE CELLS WITHIN THE RESPIRATORY SYSTEM | Non-Final OA | Cila Therapeutics Inc. |
| 18122221 | SUGAR-COATED MELANIN NANOPARTICLES AND METHOD FOR TARGETING METASTATIC CANCER CELLS | Non-Final OA | NATIONAL SCIENCE FOUNDATION |
| 18684335 | BROAD SPECTRUM ANTI-MICROBIAL POLYMERIC COMPOSITION | Non-Final OA | CORNELL UNIVERSITY |
| 18166339 | CO-AMORPHOUS FORM OF A SUBSTANCE AND A PROTEIN | Non-Final OA | University of Copenhagen |
| 18036397 | MEDICATION THAT PROTECTS THE INTESTINAL MICROBIOTA AND THEIR PREPARATION METHODS AND APPLICATIONS | Non-Final OA | UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA |
| 18245559 | Multi-targeting cell-derived nanoparticles as a versatile theranostic | Final Rejection | Fondazione Istituto Italiano di Tecnologia |
| 18392143 | COMPOSITIONS AND SYSTEMS COMPRISING TRANSFECTION-COMPETENT VESICLES FREE OF ORGANIC-SOLVENTS AND DETERGENTS AND METHODS RELATED THERETO | Non-Final OA | The University of British Columbia |
| 18144382 | IN VIVO IMMUNOIMAGING OF INTERFERON-GAMMA | Non-Final OA | Wayne State University |
| 18591479 | STABILIZATION OF ADJUVANTED VACCINE COMPOSITIONS AND THEIR USE | Non-Final OA | Vaxcyte, Inc. |
| 18281915 | LIPID NANOPARTICLE PREPARATION METHOD AND PREPARATION APPARATUS THEREFOR | Non-Final OA | INVENTAGE LAB INC. |
| 18555439 | "Good" buffer-based cationic lipids | Final Rejection | TRANSLATE BIO, INC. |
| 18004182 | Liposome formulations | Final Rejection | Thermosome GmbH |
| 18570611 | SUB-MICRON PARTICLE | Non-Final OA | IMPERIAL COLLEGE INNOVATIONS LIMITED |
| 18576244 | IONIZABLE LIPID COMPOUND FOR NUCLEIC ACID DELIVERY AND LNP COMPOSITION THEREOF | Non-Final OA | CANSINO (SHANGHAI) BIOLOGICAL RESEARCH CO., LTD. |
| 18266986 | WNT+ ADIPOCYTES, EXOSOMES FROM WNT+ ADIPOCYTES, AND METHODS OF MAKING AND USING THEM | Non-Final OA | The Administrators of the Tulane Educational Fund |
| 18521172 | LIPID NANOPARTICLES AND METHODS OF USE THEREOF | Non-Final OA | ReNAgade Therapeutics Management Inc. |
| 18270844 | USE OF PLANT-DERIVED EXOSOMES FOR INDUCING DIFFERENTIATION OF STEM CELL SOURCES INTO CARTILAGE AND BONE CELLS | Non-Final OA | YEDITEPE UNIVERSITESI |
| 18388724 | PARTICLE COMPOSITIONS COMPRISING POLYSARCOSINE LIPID CONJUGATES | Final Rejection | CALUSA BIO, LLC |
| 18387453 | METHODS OF PREPARATION OF NOVEL PAN TLR ANTAGONISTIC LIPOSOMAL-LNP FORMULATIONS AND USES THEREOF | Non-Final OA | Celestial Therapeutics Inc. |
| 18556287 | FUNCTIONALIZED BIOCATALYTICAL COMPOSITIONS | Non-Final OA | PERSEO PHARMA AG |
| 18381305 | BILIRUBIN NANOPARTICLE, USE THEREOF, AND PREPARATION METHOD THEREFOR | Final Rejection | BILIX CO., LTD. |
| 17615637 | Compositions of Dicarboxylic Acid Derivatives | Non-Final OA | UPL LTD |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy